Audited Financial Results as on 31st March 2026.
NATHBIOGEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 8.1 pts less than Nifty Microcap 250 and 8.2 pts less than its Other Agricultural Products peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Nath Bio-Genes reported FY 2025-26 revenue of Rs 4,316 crore, up 19.1% from Rs 3,623 crore in the prior year. Net profit grew 5.4% to Rs 444.26 lakh from Rs 421.40 lakh. However, EBITDA margin compressed from ~13.4% to ~11.3% due to rising production expenses. The company declared a dividend of Rs 2 per share (20%). The auditor issued an unmodified (clean) opinion but included an Emphasis of Matter noting recovery of Rs 600.73 lakh against previously provisioned advances to farmers, and pending confirmations on certain receivables, payables and loans. Operating cash flow turned negative at Rs -139.14 lakh due to inventory build-up and working capital changes.
Positive revenue momentum but margin compression is a concern. Clean audit with no going concern issues is reassuring. The negative operating cashflow and large outstanding income tax disputes (totaling Rs 6,610 lakh across multiple years) warrant attention.